Pityriasis alba: toward an effective treatment

Background Pityriasis alba is a common skin condition that may be challenging to treat, especially in patients with darker skin type where the hypopigmentation may be more noticeable and represents a major cosmetic concern. Objectives This study aims to evaluate the efficacy of three cost-effective treatments of PA in comparison with placebo. Patients/Methods This prospective study was conducted on 80 patients complaining from PA and divided into 4 equal groups according the received topical treatment on the target lesions twice daily for 8 weeks (Calcipotriol 0.005% cream, Tacrolimus 0.03% ointment, topical corticosteroid; Clobetasone butyrate 0.05% cream and Petrolatum as Placebo). Clinical evaluation, Physician Global Assessment, Patient's satisfaction levels as well as point counting planimetry were done for evaluation of the response. Results Significant improvement of scaling and erythema within 3 weeks after initiation of therapy and hypopigmentation by the 8th week, except for those received placebo. Tarolimus 0.03% ointment showed simple superiority over both Calcipotriol 0.005% cream and topical corticosteroid as regards repigmenation, although, the later received the highest level of patient satisfaction. Conclusion The three treatments were superior to placebo with relative superiority to Tacrolimus 0.03% due to limited side effects.

Automated summary

The study demonstrated significant improvement in pityriasis alba with all three treatments, with tacrolimus 0.03% ointment showing the best repigmentation effect. However, topical corticosteroid received the highest level of patient satisfaction among the treatments.